お知らせ • Oct 20
International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025 On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents. お知らせ • May 19
International Isotopes Inc., Annual General Meeting, Jul 10, 2025 International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States お知らせ • May 01
International Isotopes Inc., Annual General Meeting, Jul 10, 2024 International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting. お知らせ • May 25
International Isotopes Inc., Annual General Meeting, Jul 12, 2023 International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting. お知らせ • May 09
International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective Immediately International Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.